title: In vitro effect of cefodizime, imipenem/cilastatin and co-trimoxazole on dexamethasone and cyclosporin A depressed phagocytosis.
abstract: Phagocytosis is an important part of the host defense against infection. Antibiotics can influence phagocytic function. In the present study, leukocyte metabolic response to phagocytic challenge by latex was assessed in relation to in vitro addition of cotrimoxazole, imipenem/cilastatin, cefodizime, dexamethasone (DXM), and/or cyclosporin A (CsA). Using latex particles as phagocytic challenge, glucose-1-14C utilization and 14CO2 production were measured by liquid scintillation counting. The phagocytic response was impaired by in vitro addition of DXM or CsA and this setup was used as an experimental model of immunodepression. The addition of co-trimoxazole to control samples (without DXM or CsA) depressed the response to latex challenge, whereas imipenem and cefodizime had a neutral effect. In the presence of DXM, co-trimoxazole induced a further decrease. The depressive effect of DXM was partially neutralized in the presence of cefodizime. With CsA depression, co-trimoxazole also induced a further decrease, imipenem had a neutral effect, while cefodizime partially restored the CsA suppressed reaction. Co-trimoxazole depressed the phagocytic response, imipenem had a neutral effect, whereas cefodizime restored the experimentally induced immunosuppression.
authors.affiliation: Dept. of Internal Medicine, University Hospital, Gent, Belgium.
authors.forename: A
authors.initials: A
authors.lastname: Dhondt
authors.forename: R
authors.initials: R
authors.lastname: Vanholder
authors.forename: M A
authors.initials: MA
authors.lastname: Waterloos
authors.forename: G
authors.initials: G
authors.lastname: Glorieux
authors.forename: R
authors.initials: R
authors.lastname: De Smet
authors.forename: S
authors.initials: S
authors.lastname: Ringoir
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002439:Cefotaxime / Q000031:analogs & derivatives / Q000494:pharmacology; D002511:Cephalosporins / Q000494:pharmacology; D015377:Cilastatin / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology*; D003907:Dexamethasone / Q000494:pharmacology*; D004347:Drug Interactions; D005260:Female; D005947:Glucose / Q000378:metabolism; D006801:Humans; D015378:Imipenem / Q000494:pharmacology; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007840:Latex / Q000276:immunology; D008297:Male; D010586:Phagocytes / Q000187:drug effects* / Q000276:immunology / Q000378:metabolism; D011480:Protease Inhibitors / Q000494:pharmacology; D018709:Statistics, Nonparametric; D013845:Thienamycins / Q000494:pharmacology; D015662:Trimethoprim, Sulfamethoxazole Drug Combination / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D002511:Cephalosporins; D007166:Immunosuppressive Agents; D007840:Latex; D011480:Protease Inhibitors; D013845:Thienamycins; D015377:Cilastatin; D015378:Imipenem; D003907:Dexamethasone; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D016572:Cyclosporine; D005947:Glucose; D002439:Cefotaxime; C033356:cefodizime